Patent Grant
10941196
A Sequence Listing submitted as an ASCII text file via EFS-Web is hereby incorporated by reference in accordance with 35 U.S.C. § 1.52(e). The name of the ASCII text file for the Sequence Listing is 31142945_1.TXT, the date of creation of the ASCII text file is Aug. 15, 2019, and the size of the ASCII text file is 32.2 KB.
The present invention relates to de-immunogenicity of anti-Tumor Necrosis Factor-alpha (TNF-α) antibodies and applications of using the same for treating inflammatory diseases and other human diseases.
TNF is an immunity-modulating cytokine required for immune processes. The unregulated activities of TNFs can lead to the development of inflammatory diseases. Excess amounts of TNF-expressed in cells are associated with the development of immune diseases, including rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and inflammatory bowel disease. The function of TNF requires binding to its two receptors, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). Blocking the interaction between TNF and TNFRs has successfully been developed as a therapy in treating inflammatory or autoimmune diseases. TNF neutralization therapies, including the use of a soluble TNFR2-Fc recombinant (Etanercept), a mouse-human chimera mAb (Infliximab), or a human mAb (Adalimumab), have been introduced in the past decades for the management of rheumatoid arthritis and other immune diseases.
However, although it is fully human antibody, high immunogenicity has been observed in human patients treated with Adalimumab. Anti-drug antibody (ADA) to Adalimumab was detected in up to 75% of the patients. It was also reported that the annual loss of response to Adalimumab was calculated to be 24%. ADA was considered as the causes of treatment failures, and it is believed that ADAs might reduce drug efficacy by competing with the endogenous ligand (neutralizing antibodies, Nab) and/or by forming immune complex, which accelerate the clearance of the drug from the circulation. Therefore there is need to develop a better anti-TNF antibody with lower immunogenicity and longer efficicay.
This invention is about the de-immunogenicity of human anti-Tumor Necrosis Factor-alpha (TNF-α) antibody Adalimumab, designed as clones TCX002-L3H4, L1H4. etc, which bind to the same epitope from the one recognized by Adalimumab, but with much lower immunogenicities in vivo.
The present invention provides the human anti-Tumor Necrosis Factor-alpha (TNF-α) antibodies with reduced immunogenicities and methods of using the same for neutralizing the TNF-α induced cell death and for treating inflammatory diseases and other human diseases. In one aspect, the present invention features TNF-α-binding molecules and their DNA and amino acid sequences. Each molecule comprises the CDRs from human anti-TNF-α monoclonal antibody Adalimumab and the FRs from different human origins.
The present invention also provides a method to develop human antibodies with reduced immunogenicities by replacing the FRs of the original human monoclonal antibody with the FRs from different human origins.
In addition, the present invention also provides one example of using the method to develop human anti-TNF-α antibodies with reduced immunogenicities by replacing the FRs of human anti-TNF-α monoclonal antibody Adalimumab with the FRs from different human origins.
The present invention features de-immunized human anti-TNF-α antibodies with one of the amino acid sequences of light chains shown in SEQ ID NO. 11˜15 or 23, and one of the amino acid sequences of heavy chains shown in SEQ ID NO. 16˜20.
Furthermore, the present invention features de-immunized human anti-TNF-α antibodies with one of the DNA sequences of light chains L1-L5 shown in SEQ ID NO. 1˜5, and one of the DNA sequences of heavy chains h1-h5 shown in SEQ ID NO. 6˜10.
Furthermore, the present invention features de-immunized human anti-TNF-α antibody with the the amino acid sequence of light chains shown in SEQ ID NO. 13, and the amino acid sequences of heavy chain shown in SEQ ID19.
Furthermore, the present invention features de-immunized human anti-TNF-α antibody with the DNA sequence of light chain shown in SEQ ID NO. 3, and the DNA sequence of heavy chain shown in SEQ ID. 9
The present invention provides the sequences for 10 de-immunized human anti-TNF-α antibodies, named as L3h2, L3h4, L5h2, L4h1, L4h2, L4h4, L1h3, L2h1, L0h4 and L2h5, which have similar affinities as the original and can block the binding of TNF-α to its receptors TNFRs p55 and p75.
Whereas, the de-immunized human anti-TNF-α antibody L3h2 with the amino acid sequence of light chains shown in SEQ ID NO. 13 and the amino acid sequences of heavy chain shown in SEQ ID No. 17, and with the DNA sequence of light chain shown in SEQ ID NO. 3, and the DNA sequence of heavy chain shown in SEQ ID No. 7.
Whereas, the de-immunized human anti-TNF-α antibody L3h4 with the amino acid sequence of light chains shown in SEQ ID NO. 13 and the amino acid sequences of heavy chain shown in SEQ ID No. 19 and with the DNA sequence of light chain shown in SEQ ID NO. 3, and the DNA sequence of heavy chain shown in SEQ ID No. 9.
Whereas, the de-immunized human anti-TNF-α antibody L5h2 with the amino acid sequence of light chains shown in SEQ ID NO. 15 and the amino acid sequences of heavy chain shown in SEQ ID No. 17, and with the DNA sequence of light chain shown in SEQ ID NO. 5, and the DNA sequence of heavy chain shown in SEQ ID No. 7.
Whereas, the de-immunized human anti-TNF-α antibody L4h1 with the amino acid sequence of light chains shown in SEQ ID NO. 14 and the amino acid sequences of heavy chain shown in SEQ ID No. 16, and with the DNA sequence of light chain shown in SEQ ID NO. 4, and the DNA sequence of heavy chain shown in SEQ ID No. 6.
Whereas, the de-immunized human anti-TNF-α antibody L4h2 with the amino acid sequence of light chains shown in SEQ ID NO. 14 and the amino acid sequences of heavy chain shown in SEQ ID No. 17, and with the DNA sequence of light chain shown in SEQ ID NO. 4, and the DNA sequence of heavy chain shown in SEQ ID No. 7.
Whereas, the de-immunized human anti-TNF-α antibody L4h4 with the amino acid sequence of light chains shown in SEQ ID NO. 14 and the amino acid sequences of heavy chain shown in SEQ ID No. 19, and with the DNA sequence of light chain shown in SEQ ID NO. 4, and the DNA sequence of heavy chain shown in SEQ ID No. 9.
Whereas, the de-immunized human anti-TNF-α antibody L1h3 with the amino acid sequence of light chains shown in SEQ ID NO. 11 and the amino acid sequences of heavy chain shown in SEQ ID No. 18, and with the DNA sequence of light chain shown in SEQ ID NO. 1, and the DNA sequence of heavy chain shown in SEQ ID No. 8.
Whereas, the de-immunized human anti-TNF-α antibody L2h1 with the amino acid sequence of light chains shown in SEQ ID NO. 12 and the amino acid sequences of heavy chain shown in SEQ ID No. 16, and with the DNA sequence of light chain shown in SEQ ID NO. 2, and the DNA sequence of heavy chain shown in SEQ ID No. 6.
Whereas, the de-immunized human anti-TNF-α antibody L2h5 with the amino acid sequence of light chains shown in SEQ ID NO. 12 and the amino acid sequences of heavy chain shown in SEQ ID No. 20, and with the DNA sequence of light chain shown in SEQ ID NO. 2, and the DNA sequence of heavy chain shown in SEQ ID No. 10.
Whereas, the de-immunized human anti-TNF-α antibody L0h4 with the amino acid sequence of light chains shown in SEQ ID NO. 23 and the amino acid sequences of heavy chain shown in SEQ ID No. 19, and with the DNA sequence of light chain shown in SEQ ID NO. 21, and the DNA sequence of heavy chain shown in SEQ ID No. 9.
The present invention features the expression plasmid containing the de-immunized anti-TNF-α antibody sequences.
The present invention also covers the plasmid, the host cells containing the de-immunized anti-TNF-α antibody sequences.
The invention also provides de-immunized anti-TNF-α antibodies for treatment of human diseases targeting TNF-α.
The TNF-α-binding molecules or antibodies of the present invention can be used to inhibit the death of cells.
In addition, the TNF-A-binding molecules or antibodies of the present invention can be used to treat human diseases including rheumatoid arthritis, Crohn's disease, psoriatic arthritis, and inflammatory bowel disease. These methods comprise administrating an effective amount of a TNF-α-binding molecule or antibody of the present invention to a subject in need thereof.
Furthermore, the present invention also features pharmaceutical and diagnostic compositions comprising a TNF-α-binding molecule or antibody of the present invention.
The present invention provides the method of de-immunogenicity of anti-TNF-α monoclonal antibody, including:
It should be understood that the above-described embodiments and the following examples are given by way of illustration, not limitation. Various changes and modifications within the scope of the present invention will become apparent to those skilled in the art from the present description.
Unless specified, all the techniques used are common practices and can be performed by skilled personnel. All of the materials and reagents can be purchased commercially.
Adalimumab
Used a program to examine the sequences of Adalimumab and found that the immunogenicity score is 16.
Used the same software to study the immunogenicities of the FRs of Adalimumab, identified the sequences with high immunogenicities, and searched human antibody sequence database for potential human sequences with lower immunogenicity.
Replaced the high immunogenic sequences in Adalimumab with the low immunogenic ones, and designed 5 human light chains L1-L5 (SEQ ID No. 1-5) and 5 human heavy chains h1-h5 (SEQ ID No. 6-10) for fully human anti-TNF-α monoclonal antibodies.
Perform 3D structure modeling of the newly designed antibody sequences against the ones of Adalimumab using Pymol program to identify the ones with closest resembling of the original antibody.
Fully human anti-TNF-α monoclonal antibodies can be any combination of one light chain from any one of L0-L5 (SEQ ID No. 1-5, 21) and one heavy chain from any one of h1-h5 (SEQ ID No. 6-10).
Added the restriction sites of Kpn I and BamH I to the light chain variable region sequences and the restriction sites of Kpn I and Age I to the heavy chain variable region sequences obtained in Example 1. All the variable region of the light and heavy chain sequences were inserted into the plasmids. Cut the heavy chain variable region sequences from the plasmids and inserted into the corresponding sites of the expression vector pJH16 using the restriction sites of Kpn I and Age I. Cut the light chain variable region sequences from the vector and inserted into the corresponding sites of the expression vector pJH16 using the restriction sites of Kpn I and BamH I, to obtain the fully human monoclonal antibody heavy and light chain expression plasmids. The plasmids and the expression vectors were subjected to enzyme digestions at 37 C overnight. Results of digestions of light chain, heavy chain, and the expression vectors are shown in
Extracted the plasmids from the transformed E. coli DH5a, as shown in Example 2, using the Ultrapure Plasmid Prep kit from Qiagen.
Co-transfected the 293F cells with different combinations of the human light and heavy chain expression plasmids using lipofecting reagents from Invitogen. Total 31 combinations tried.
The expression levels of human IgGs in the culture supernants were examined on Day 3 and the expression levels ranged between 423.5-2624 ng/ml.
Based on above data, 10 combinations were selected to develop stable cell lines for over-expression of human anti-TNF-α.
CHO cells was electro-transfected and selected under MTX pressure (purchased from Sigma) in the selective Opti-CHO medium (purchased from Invitrogen). Five selecting gradients were set as 50 nM, 100 nM, 200 nM, 400 nM and 800 nM. After each round, the expression levels of IgG in the culture supernatants on Day 7 were examined using Sandwich ELISA method. The results showed that stable expressions of IgGs were observed with all of the combinations but the levels were different (Table 3).
When the process was complete, limiting dilution was performed for monoclonal cloning. Cells were seeded at 96-well plate and cultured at 37° C. 5% CO2. 14 days later, 50 μl of supernatant was collected for antibody production testing using sandwich ELISA method. Clones with higher expressing levels were selected for further expansion.
Used a Protein-A affinity chromatography column to purify the human anti-TNF-α antibodies from the culture supernatants of the 11 stable cell lines. The concentrations of antibodies were determined by OD280/1.4. The purities of the antibodies were examined by SDS-PAGE analysis.
1. Affinities: The EC50s of the newly invented human anti-TNF-α antibodies were compared with the one of Adalimumab using Indirect ELISA. The wells of 96-well plates were coated with 300 ng/ml of TNF-α in PBS overnight at 4 C. After wash, the wells were blocked with 5% skim milk in PBS for 1 hour at room temperature. Various concentrations of antibodies diluted in 5% skim milk-PBS were added to the wells and incubated for 1 hour at room temperature. After another wash, HRP-conjugated goat-anti-human IgG secondary antibodies were added and incubated for another 1 hour. After through wash, the substrates were added and the absorbances at 450 nm were measured. As shown in Table 4, some of the newly invented human anti-TNF-α antibodies have very similar EC50 as Adalimumab.
2. Specificities: The specificities of the newly invented human anti-TNF-α antibodies were examined by Indirect ELISA against TNF-α and other cytokines. The wells of 96-well plates were coated with 1000 ng/ml of rhTNFα, rhTNFβ, rIFN γ, IL-1α, IL-1β, IL-2, IL-4 and IL-8 in PBS overnight at 4 C. After wash, the wells were blocked with 5% skim milk in PBS for 1 hour at room temperature. Different human anti-TNF-α antibodies diluted in 5% skim milk-PBS were added to the wells and incubated for 1 hour at room temperature. After another wash, HRP-conjugated goat-anti-human IgG secondary antibodies were added and incubated for another 1 hour. After through wash, the substrates were added and the absorbances at 450 nm were measured. As shown in Table 5, all of the newly invented human anti-TNF-α antibodies are very specific for TNF-α.
3. Inhibition of TNF-α induced apotosis.
L929 cells were seeded at 50,000 cells/well of 96-well plate in RPMI-1640-10% FBS and incubated at 37° C. 5% CO2. 4 hours later, discard the medium and added 100 μl/well of different concentrations of ADALIMUMAB or the invented human anti-TNF-α antibodies in RPMI-1640-10% FBS plus Actinomysin D 1 ug/ml at 37° C. 5% CO2. One day's later, the cell numbers in each well were determined by CKK assay.
As shown in
1. Immunogenicity: Mice were injected with all 10 new human anti-TNF-α antibodies and Adalimumab with the adjuvant. 14 days' later, the tail bleeds were examined by ELISA against their antigens respectively. As shown in Table 6, the anti-drug antibody titers of some newly invented human anti-TNF-α antibodies were at least 5-time lower than the one of Adalimumab.
2. Pharmakintics: Mice were tail vent-injected with 125 I—labeled all 10 new human anti-TNF-α antibodies and Adalimumab (370 kBq, 2 μg), 5 mice per group. At various time points (5, 12, 30 min, 1, 2, 4, 8, 11, 22, 34, 48, 72 h), the blood samples were collected and the radioactivities were measured. As shown in
The invention features human anti-TNF-α antibodies which share the CDRs of the amino acid sequences from Adalimumab but with different FRs from other human IgGs. The newly invented human anti-TNF-α antibodies have the same specificities, similar affinities and inhibitory activities against TNF-α but much lower immunogenicities than Adalimumab. The invention also features method of de-immunogenicity of human antibodies by replacing the high immunogenic FR sequences with lower ones from other human IgGs without alter the activities of the antibody significantly. Reduced immunogenicity will significantly reduce the level of anti-drug antibody in the patients treated with anti-TNF-α drug, extend drug's half-life and increase the efficacy of the biological drugs.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201410390493.4 | Aug 2014 | CN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2015/074528 | 3/18/2015 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2016/019726 | 2/11/2016 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 20100266613 | Harding et al. | Oct 2010 | A1 |
| 20150368335 | Banerjee et al. | Dec 2015 | A1 |
| Number | Date | Country |
|---|---|---|
| 102439040 | May 2012 | CN |
| 102755646 | Oct 2012 | CN |
| WO-2009083246 | Jul 2009 | WO |
| Entry |
|---|
| Van Schouwenburg et al., Nature Reviews Rheumatology vol. 9, pp. 164-172 (2013). (Year: 2013). |
| EP examination report dated Apr. 15, 2019 in conjunction with the EP equivalent to the instant application, pp. 1-4. (Year: 2019). |
| International Search Report dated Jun. 29, 2015 in International Application No. PCT/CN2015/074528, filed Mar. 18, 2015, in 11 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20170327570 A1 | Nov 2017 | US |
